The patient recovering from alcohol or drug addiction: Special issues for the anesthesiologist

Anesthesia and Analgesia

Volumn 92, Issue 6, 2001, Pages 1601-1608

  May, Judith A ^a   White, Herbert C ^c   Leonard White, Ardis ^c   Warltier, David C ^a,b   Pagel, Paul S ^a,c  

^a Department of Anesthesiology ^*  (United States)

^b Division of Cardiovascular Diseases

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ANTICONVULSIVE AGENT; CALCIUM CARBIMIDE; DISULFIRAM; METHADONE; NALMEFENE; NALTREXONE; SEROTONIN UPTAKE INHIBITOR;

ALCOHOLISM; ANALGESIA; ANESTHESIOLOGICAL TECHNIQUES; ANESTHESIST; ARTICLE; CONVALESCENCE; DRUG DEPENDENCE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RELAPSE; RISK BENEFIT ANALYSIS;

EID: 0035007315     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200106000-00050     Document Type: Article

References (76)

1. Alcoholism and anesthesia
2. The drug addicted patient
3. Management of the recovering alcoholic who seeks cosmetic surgery
4. Addiction in the treatment of pain: Significance, recognition, and management
5. Prescription of opioids for treatment of pain in patients with addictive disease
6. Principles of pain treatment in the addicted patient
7. Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: Report of 20 cases
8. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
9. Myths about the treatment of addiction
10. Drug abuse: Hedonic homeostatic dysregulation
11. A commentary on neurotransmitter restoration as a common mode of treatment for alcohol, cocaine and opiate abuse
12. Addiction is a brain disease, and it matters
13. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation
14. Brain reward mechanisms
15. Molecular and cellular basis of addiction
16. Drug addiction: The yin and yang of hedonic homeostasis
17. Rational recovery, SMART recovery, and non-twelve step recovery programs
18. Inpatient treatment of alcoholism: New life for the Minneapolis plan
19. Substance abuse day treatment and managed health care
20. Alcoholism treatment: A ten-year follow-up study
21. Overview of pharmacological treatment approaches for alcohol and other drug addiction: Intoxication, withdrawal, and relapse prevention
22. Pharmacologic treatments for drug and alcohol dependence
23. The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization
24. The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence
25. Anesthetic implications of concurrent diseases
26. Techniques to enhance compliance with disulfiram
27. Inactivation of horse liver mitochondrial aldehyde dehydrogenase by disulfiram: Evidence that disulfiram is not an active-site-directed reagent
28. The actions and metabolic fate of disulfiram
29. Hypnotics and sedatives: Ethanol
30. Calcium carbimide in alcoholism treatment. Part 1. A placebo-controlled, double-blind clinical trial of short-term efficacy
31. Naltrexone in the treatment of alcohol dependence
32. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence
33. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence
34. Alternative pharmacotherapies for opiate addiction
35. Naltrexone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence
36. Acamprosate in alcohol dependence: How does it work?
37. Relapse prevention by acamprosate: Results from a placebo controlled study on alcohol dependence
38. The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal
39. Alcohol withdrawal and limbic kindling: A hypothesis of relapse
40. Calcium-diacetyl-homotaurinate which prevents relapse in weaned alcoholics decreases the action of excitatory amino acids in neocortical neurons of the rat in vitro
41. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence
42. Treatment of comorbid affective and substance use disorders: Therapeutic potential of anticonvulsants
43. A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin
44. Accelerated recovery from doxacurium-induced neuromuscular blockade in patients receiving chronic anticonvulsant therapy
45. Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients
46. Fluoxetine in depressed alcoholics: A double-blind, placebo-controlled trial
47. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics
48. Buspirone treatment of anxious alcoholics: A placebo-controlled trial
49. Unusual hypotension and bradycardia in a patient receiving fenfluramine, phentermine, and fluoxetine
50. A medical treatment for diacetylmorphine (heroin) treatment: A clinical trial with methadone hydrochloride
51. LAAM: Pharmacology, pharmacokinetics, developmental history, and therapeutic considerations
52. Development of buprenorphine for the treatment of opioid dependence
53. Comparison of acetylmethadol and methadone in the treatment of long-term heroin users: A pilot study
54. Buprenorphine treatment of opioid dependence: A review
55. Methadone maintenance
56. Anesthesia and analgesia
57. Knowledge of medical students, residents and attending physicians about opiate abuse
58. Relapse prevention
59. The role of stress in drug self-administration
60. Irrational attitudes toward addicts and narcotics
61. Education and training in addictive diseases
62. An assessment of hospital care for the alcoholic patient
63. Psychoanalysis and substance abuse: Toward a more effective approach
64. Survey of attitudes among three specialists in a teaching hospital toward alcoholics
65. Fallacies and phobias about addiction and pain
66. Pain and its treatment in outpatients with metastatic cancer
67. Drug therapy: Butorphanol
68. Dezocine: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy
69. Intravenous opioid anesthetics
70. Opioids, pain and behavioral outcomes
71. Opioid pseudoaddiction: An iatrogenic syndrome